These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28366594)

  • 1. Opportunities for Collaboration at the Interface of Pharmacovigilance and Manufacturing.
    Beninger P
    Clin Ther; 2017 Apr; 39(4):702-712. PubMed ID: 28366594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
    Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H
    Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance: An Overview.
    Beninger P
    Clin Ther; 2018 Dec; 40(12):1991-2004. PubMed ID: 30126707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
    Lam S
    Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stemming the global trade in falsified and substandard medicines.
    Gostin LO; Buckley GJ; Kelley PW
    JAMA; 2013 Apr; 309(16):1693-4. PubMed ID: 23579391
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage.
    Panzitta M; Ponti M; Bruno G; Cois G; D'Arpino A; Minghetti P; Mendicino FR; Perioli L; Ricci M
    Int J Pharm; 2017 Jan; 516(1-2):144-157. PubMed ID: 27838294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forensic pharmacovigilance and substandard or counterfeit drugs.
    Labadie J
    Int J Risk Saf Med; 2012; 24(1):37-9. PubMed ID: 22436258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal Management in Pharmacovigilance: A Review of Activities and Case Studies.
    Beninger P
    Clin Ther; 2020 Jun; 42(6):1110-1129. PubMed ID: 32487428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.